GlassScriptPhysician profile
Syed A Akbar
NPI 1174574222
$569.00
in general payments reported to CMS, 2019-2025
15 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.34 · 2022: $17.23 · 2023: $127 · 2024: $222 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $129.45 | 2024 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Tersera Therapeutics LLC | $126.81 | 2023-2025 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $58.01 | 2023 | |
| Jazz Pharmaceuticals INC. | $42.94 | 2025 | |
| Celgene Corporation | $26.57 | 2025 | Reblozyl |
| Sobi, INC | $24.25 | 2025 | |
| Genzyme Corporation | $22.88 | 2025 | |
| Mirati Therapeutics, INC. | $20.84 | 2023 | Krazati |
| Genentech USA, INC. | $19.94 | 2025 | Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $18.17 | 2023 | Iclusig |
| Glaxosmithkline, LLC. | $17.74 | 2024 | Jemperli, Zejula |
| Myovant Sciences INC. | $17.23 | 2022 | |
| Kite Pharma, INC. | $16.40 | 2025 | Yescarta |
| Coherus Oncology, INC. | $15.43 | 2024 | |
| Urogen Pharma, INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Akbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.